BMO Downgrades ResMed (RMD) to Market Perform; $41 PT
BMO Capital downgrades ResMed (NYSE: RMD) from Outperform to Market Perform. The firm has a $41 price target on the stock.
ResMed, Inc. engages in the design, manufacture, and marketing of equipment for the diagnosis and treatment of -disordered breathing, including obstructive sleep apnea, and other respiratory disorders that occur during sleep.
Related Categories
DowngradesStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
